• Analyst Coverage
• Corporate Governance
• Email Alerts
• FAQ
• Financial Reports
• Fundamentals
• Image Library
• Information Request
• Investor Events
• SEC Filings
• Presentation Archive
• Press Releases
• Stock Chart
• Stock Quote
• Worth Noting

Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Signs Agreement to Acquire Minority Interest in HuBit Genomix

Rockville, MD and Tokyo, Japan - March 21, 2001

Celera Genomics (NYSE: CRA), an Applera Corporation business, announced today that it has signed an agreement to acquire a minority interest in HuBit Genomix, Inc., an emerging biotechnology company based in Japan. Financial terms of the transaction were not disclosed.

“This agreement represents an important opportunity for both companies as it should allow HuBit to expand its research and development in analyzing genetic variation, potentially involving Celera as a business and scientific partner in these important areas, ” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. “HuBit’s management team encompasses some of the finest scientific and business leaders in Japan and we are pleased to be working with them.”

“We are very excited to be working with Celera, a company known for remarkable accomplishments and first class molecular biologists and bioinformatic professionals. We believe that both Celera and HuBit share a similar spirit for speed and innovation. This agreement should help us not only to promote our research and business activities, but also to enhance our contribution to global genomic research advancements,” said H. Kimura, Ph.D., HuBit’s CEO.

About HuBit Genomix
HuBit Genomix, Inc. was founded as Medical Genome Systems, Inc. in April 2000 and capitalized through an investment from CSK Venture Capital. HuBit is initially focused on the discovery and association of genes, particularly single nucleotide polymorphisms, or SNPs, and disease, for use in the development of therapeutics and diagnostics. HuBit plans to provide its biological information to pharmaceutical, biotechnology companies and research centers located in Japan and elsewhere.

About Celera
Applera Corporation, formerly PE Corporation, comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to be the definitive source of genomic and related medical information. Celera has developed three business units: the On-line Information Business, Discovery Sciences, and Discovery Services, all of which build upon Celera’s generation, integration, and analysis of biological information. Celera intends to enable therapeutic and diagnostic discoveries both through its own application of its scientific capabilities and in partnership with pharmaceutical and biotechnology companies. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.